OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

J. Randolph (Randy) Hecht, MD

Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors

Qian (Janie) Qin, MD

Dr Qin on Emerging Treatment Options in ccRCC

Ajai Chari, MD

Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

Joachim G. J. V. Aerts, MD, PhD

Dr Aerts on Results From the DENIM Trial of Dendritic Cell Vaccination in Mesothelioma

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

Naval G. Daver, MD

Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML

Pasi A. Jänne, MD, PhD

Dr Jänne on Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Dr Pothuri on the Use of ADCs in Ovarian Cancer

Dr Pothuri on the Use of ADCs in Ovarian Cancer

Saad Z. Usmani, MD, MBA, FACP

Dr Usmani on Unmet Needs in the Treatment of High-Risk Multiple Myeloma

J. Randolph (Randy) Hecht, MD

Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors

Alessandro Di Federico, MD

Dr Di Federico on an Analysis of TTF-1 Expression in Lung Adenocarcinoma

Qian (Janie) Qin, MD

Dr Qin on Ongoing Investigations of Belzutifan Combinations in Advanced ccRCC

Judy C. Boughey, MD

Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast Cancer

Tian Zhang, MD, MHS

Dr Zhang on the Use of Radiation Therapy for Oligometastatic RCC

Francisco J. Esteva, MD, PhD

Dr Esteva on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Dazhi Liu, PharmD, MS, BCOP

Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC

Martin Cannon, PhD

Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian Cancer

Johannes Schetelig, MD, MSc, head, Stem Cell Transplantation Unit, University Hospital TU Dresden, head, DKMS Clinical Trials Unit,

Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AML

John Seymour, MBBS, FRACP, PhD

Dr Seymour on Patient Subsets That May Benefit From Curative FCR in CLL

Steven Park, MD

Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FL

Stephen V. Liu, MD

Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC

Ajai Chari, MD,

Dr Chari on the Evolving Role of Bispecific Antibodies and CAR T-Cell Therapy in Multiple Myeloma

Tycel Phillips, MD, MPH

Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FL

Terufumi Kato, MD

Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

Sanam Loghavi, MD

Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML

Bhavana Pothuri, MD

Dr Pothuri on Treating Patients With Ovarian Cancer

Loretta J. Nastoupil, MD

Dr Nastoupil on the Use of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

Tycel Phillips, MD, MPH

Dr Phillips on Treatment With Bispecific Antibodies and CAR T-Cell Therapy in MCL

Stephanie L. Graff, MD

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

Peter Riedell, MD

Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FL

12345678
...
397>